The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

European Urology

Volumn 50, Issue 5, 2006, Pages 873-878

  Clarke, Noel W ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; TUMOR MARKER;

BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RESEARCH; CANCER THERAPY; EDITORIAL; HUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; PROSTATE CANCER;

BONE AND BONES; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIONUCLIDE IMAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 33749250964     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.08.033     Document Type: Editorial

References (4)

1. O'Donohue E.P.N., Constable A.R., Sherwood T., Stephenson J.J., and Chisholm G.D. Bone scanning and plasma phosphatases in carcinoma of the prostate. Br J Urol 50 (1978) 172-177
2. Fitzpatrick J.M., Constable A.R., Sherwood T., Stephenson J.J., Chisholm G.D., and O'Donohue E.P.N. Serial bone scanning: the assessment of treatment response in carcinoma of the prostate. Br J Urol 50 (1978) 555-561
3. Subramanian G., and McAfee S.G. A new compound of 99m Tc for skeletal imaging. Radiology 99 (1971) 192-196
4. Chybowski F.M., Larson-Keller J.J., Bergstrahl E.J., and Oesterling J.E. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer. Prostate specific antigen is superior to all other modalities. J Urol 148 (1992) 313-318